ASH VTE Guidelines: Anticoagulation Therapy

Clinicians confront numerous practical issues in optimizing the use of anticoagulants to treat VTE. Anticoagulant therapy is complex and associated with substantial benefits and risks. These guidelines focus on the optimal management of anticoagulant drugs for the prevention and treatment of VTE following the choice of an anticoagulant.

In July 2022, these guidelines were reviewed by an expert work group convened by ASH. Review included limited searches for new evidence and discussion of the search results. Following this review, the ASH Committee on Quality agreed to continue monitoring the supporting evidence rather than revise or retire these guidelines at this time. Limited searches and expert review will be repeated annually going forward until these guidelines are revised or retired.